BridgeBio Pharma Inc. (BBIO), a biopharmaceutical company focused on genetic diseases, will be presenting additional data on clinical outcomes from ATTRibute-CM at the European Society of Cardiology (ESC) Congress tomorrow.
ATTRibute-CM is a phase III study of the company's investigational drug Acoramidis in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). Acoramidis demonstrated a significant impact on mortality, hospitalizations, and quality of life in in ATTR-CM participants in the trial.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.